Skip to main content

Peer Review reports

From: A selective CB2R agonist (JWH133) protects against pulmonary fibrosis through inhibiting FAK/ERK/S100A4 signaling pathways

Original Submission
11 Apr 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
21 Jun 2023 Reviewed Reviewer Report - Enrico Selvi
11 Jul 2023 Reviewed Reviewer Report - Udari E. Perera
25 Jul 2023 Author responded Author comments - Yiju Cheng
Resubmission - Version 3
25 Jul 2023 Submitted Manuscript version 3
26 Jul 2023 Author responded Author comments - Yiju Cheng
Resubmission - Version 4
26 Jul 2023 Submitted Manuscript version 4
27 Jul 2023 Author responded Author comments - Yiju Cheng
Resubmission - Version 5
27 Jul 2023 Submitted Manuscript version 5
8 Aug 2023 Reviewed Reviewer Report - Udari E. Perera
17 Aug 2023 Reviewed Reviewer Report - Enrico Selvi
6 Oct 2023 Author responded Author comments - Yiju Cheng
Resubmission - Version 6
6 Oct 2023 Submitted Manuscript version 6
8 Oct 2023 Author responded Author comments - Yiju Cheng
Resubmission - Version 7
8 Oct 2023 Submitted Manuscript version 7
2 Nov 2023 Reviewed Reviewer Report - Udari E. Perera
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
3 Nov 2023 Editorially accepted
13 Nov 2023 Article published 10.1186/s12890-023-02747-3

You can find further information about peer review here.

Back to article page